The FDA has approved Boehringer Ingelheim’s Jascayd (nerandomilast) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.

Idiopathic pulmonary fibrosis is one of the more common progressive fibrosing interstitial lung diseases, primarily affecting people over 50 and more men than women. It can affect up to 3.6 million people worldwide and an estimated 200,000 people in the United States.

IPF affects the tissue surrounding the air sacs, or alveoli, in the lungs. Over time, these changes can cause permanent lung scarring (fibrosis) that makes it more difficult to breathe. Symptoms include a dry and persistent cough, shortness of breath, fatigue and finger clubbing.

Current treatments can slow the progression of the disease and improve patients’ quality of

See Full Page